The BioCapital™ Biotech Hub is a life science powerhouse

The BioCapital Biotech Hub is a cluster of high performing biotech companies in Delaware, Maryland, Washington D.C., and Virginia.  The BioCapital™ community ranks third in the life sciences industry. It is home to the second most biotechnology, medical device, and pharmaceutical companies of all major groups. This region is 3rd in NIH funding as well as patents but 4th in terms of lab space and 9th in terms of jobs. (

Here are 5 companies to watch in the BioCapital Hub:

Vanda PharmaceuticalsWashington, D.C., is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs.  They have two products on the market for psychosis and sleep-wake disorders.  They also have a robust pipeline for a variety of indications including sleep disorders (including jet lag), bipolar and Parkinson’s psychosis, hematologic malignancies, social anxiety, and atopic dermatitis.

Rivus Pharmaceuticals, Charlottesville, VA, is a leader in mitochondrial biology, is advancing a new class of medicines designed to address a primary driver of cardio-metabolic diseases: obesity. Harnessing the natural process of mitochondrial uncoupling, Rivus’ Controlled Metabolic Accelerators (CMAs) provide a new, measured approach to reducing fat throughout the body. By doing so, CMAs can reduce the risk of cardio-metabolic disease with the aim of enabling healthier lives for millions.

Indivior PharmaNorth Chesterfield, Virginia, has a mission is to discover and develop innovative medications that help transform patient lives through our industry-leading understanding of addiction and the chronic conditions and co-occurring disorders of addiction.

Indivior, is pioneering the development and discovery of non-opioid treatment strategies for OUD, as well as exploring new therapies to potentially address the needs of people suffering from alcohol, stimulant and cannabis use disorders. 

Indivior’s R&D has led to a range of daily and monthly treatment options for patients with moderate-to -severe opioid use disorder. We also developed a monthly treatment option for the treatment of schizophrenia in adult patients. 

Diffusion Pharmaceuticals, Charlottesville, VA, is an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to the areas where it is needed most.

Their lead product candidate, Trans sodium crocetinate (TSC), is a first-in-class, small molecule therapeutic with a novel mechanism-of-action that enhances the diffusion of oxygen to hypoxic tissues.

Adaptive Phage Therapeutics (APT), Gaithersburg, MD, is a clinical-stage company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria.APT’s approach arms us with the unique capability of adapting to the emergence of future antibiotic-resistant superbugs. Their phage bank’s precision targeted, genomically screened, and highly purified phage collection is dynamically expanding in response to the emergence of new strains of bacterial superbugs.